1 <u>Title</u>

- 2 Histology of type 3 macular neovascularization and microvascular anomalies in treated
- 3 age-related macular degeneration: a case study

4 Authors

- 5 Andreas Berlin MD MS,^{1,2} Diogo Cabral MD,^{3,4} Ling Chen, MD PhD,^{1,5} Jeffrey D
- 6 Messinger DC,¹ Chandrakumar Balaratnasingam MD PhD,⁶⁻⁸ Randev Mendis MD,⁹
- 7 Daniela Ferrara MD PhD,¹⁰ K. Bailey Freund MD,^{3,11} Christine A Curcio PhD^{1*}
- 8
- 9 ¹ Department of Ophthalmology and Visual Sciences, School of Medicine, University of
- 10 Alabama at Birmingham, Birmingham AL, USA;² Department of Ophthalmology,
- 11 University Hospital Wu Irzburg, Wu Irzburg, Germany; ³ Vitreous Retina Macula
- 12 Consultants of New York NY, USA; ⁴ NOVA Medical School Research, Universidade
- 13 NOVA de Lisboa, Portugal;⁵ The First Affiliated Hospital of Chongqing Medical
- 14 University, Chongqing Key Laboratory of Ophthalmology, and Chongqing Eye Institute,
- 15 Chongqing, China; ⁶ Centre for Ophthalmology and Visual Science, University of
- 16 Western Australia, Perth, Australia; ⁷ Lions Eye Institute, Nedlands, Western Australia,
- 17 Australia; ⁸ Department of Ophthalmology, Sir Charles Gairdner Hospital, Western
- 18 Australia, Australia; ⁹ Canberra Retina Center, Canberra Australia, ¹⁰ Genentech, South
- 19 San Francisco, CA, USA; ¹¹ Department of Ophthalmology, New York University
- 20 Grossman School of Medicine, New York NY, USA
- 21
- 22 *Corresponding author

23

- 24 Short title Intraretinal vascular morphologies in treated AMD
- 25 **Word count** 4117
- 26 **Figures 11**
- 27 **Tables** 2
- 28 **Supplementary** 5 figures, 1 video, 2 tables
- 29 **Corresponding Address**
- 30 Christine A. Curcio, PhD; Department of Ophthalmology and Visual Sciences; EyeSight
- 31 Foundation of Alabama Vision Research Laboratories; 1670 University Boulevard Room
- 32 360; University of Alabama at Birmingham, School of Medicine; Birmingham AL 35294-
- 33 0099; Email: <u>christinecurcio@uabmc.edu</u>

34 Key words

- 35 age-related macular degeneration, type 3 macular neovascularization, deep retinal age-
- 36 related microvascular anomalies, vascular morphology, optical coherence tomography
- 37 angiography, histopathology, electron microscopy.
- 38
- 39

Intraretinal vascular morphologies in treated AMD

40 Abstract

41 **Objective/Purpose**

- 42 To investigate intraretinal neovascularization and microvascular anomalies by correlating
- 43 in vivo multimodal imaging with corresponding ex vivo histology in a single patient.
- 44 Design
- 45 A case study comprising clinical imaging from a community-based practice, and
- 46 histologic analysis at a university-based research laboratory (clinicopathologic
- 47 correlation).

48 **Participants**

- 49 A white woman in her 90's treated with numerous intravitreal anti-vascular endothelial
- 50 growth factor (VEGF) injections for bilateral type 3 macular neovascularization (MNV)
- 51 secondary to age-related macular degeneration (AMD).

52 Intervention(s)/ Methods

- 53 Clinical imaging comprised serial infrared reflectance, eye-tracked spectral-domain
- 54 optical coherence tomography (OCT), OCT angiography, and fluorescein angiography.
- 55 Eye tracking, applied to the two preserved donor eyes, enabled correlation of clinical
- 56 imaging signatures with high-resolution histology and transmission electron microscopy.
- 57 Main Outcome(s) and Measure(s)
- 58 Histologic/ ultrastructural descriptions and diameters of vessels seen in clinical imaging.
- 59 Results
- 60 Six vascular lesions were histologically confirmed (type 3 MNV, n=3; deep retinal age-
- 61 related microvascular anomalies (DRAMA), n=3). Pyramidal (n=2) or tangled (n=1)
- 62 morphologies of type 3 MNV originated at the deep capillary plexus (DCP) and extended
- 63 posteriorly to approach without penetrating persistent basal laminar deposit. They did
- not enter the sub-RPE-BL space or cross Bruch's membrane. Choroidal contributions
- 65 were not found. The neovascular complexes included pericytes and non-fenestrated

Intraretinal vascular morphologies in treated AMD

66	endothelial cells, within a collagenous sheath covered by dysmorphic retinal pigment
67	epithelial cells. DRAMA lesions extended posteriorly from the DCP into the Henle fiber
68	and the outer nuclear layers, without evidence of atrophy, exudation, or anti-VEGF
69	responsiveness. Two DRAMA lacked collagenous sheaths. External and internal
70	diameters of type 3 MNV and DRAMA vessels were larger than comparison vessels in
71	the index eyes or aged normal and intermediate AMD eyes.
72	Conclusions
73	Type 3 MNV vessels reflect specializations of source capillaries and persist during anti-
74	VEGF therapy. The collagenous sheath of type 3 MNV lesions may provide structural
75	stabilization. If so, vascular characteristics may be useful in disease monitoring in
76	addition to fluid and flow signal detection. Further investigation with longitudinal imaging
77	before exudation onset will help determine if DRAMA are part of the type 3 MNV
78	progression sequence.
79	
80	
81	Abbreviations

82 AMD, age-related macular degeneration; BLamD, basal laminar deposit; BrM, Bruch's 83 membrane; ChC, choriocapillaris; Ch, choroid; DCP, deep capillary plexus; DRAMA, 84 deep retinal age-related microvascular anomalies; ELM, external limiting membrane; 85 ETDRS, Early Treatment Diabetic Retinopathy Study; FA, fluorescein angiography; GCL, 86 ganglion cell layer; HFL, Henle fiber layer; INL, inner nuclear layer; IPL, inner plexiform 87 layer; IS, inner segment; MNV, macular neovascularization; nvAMD, neovascular age-88 related macular degeneration; OCT, optical coherence tomography; OCTA, optical 89 coherence tomography angiography; ONL, outer nuclear layer; OPL, outer plexiform 90 layer; OS, outer segment; RPE, retinal pigment epithelium.

Intraretinal vascular morphologies in treated AMD

92 Introduction

93 Type 3 macular neovascularization (type 3 MNV) is a subtype of neovascular agerelated macular degeneration (AMD).¹ Unlike type 1 MNV, which arises from the choroid, 94 type 3 MNV originates in the neurosensory retina.^{2, 3} Female gender, older age, and 95 96 presence of subretinal drusenoid deposits confer risk for type 3 MNV.^{4, 5} Type 3 MNV is 97 diagnosed in a third of Caucasian patients presenting with unilateral neovascular AMD⁶ 98 and may be underestimated overall. Fellow eyes often convert to neovascular AMD 99 within 3 years.⁷⁻⁹ Early lesions respond well to intravitreal anti-vascular endothelial growth factor (VEGF) therapy, unlike chronic lesions.^{2, 10} New information about type 3 100 101 MNV and related vascular anomalies from histopathology, as provided herein, could 102 support improved detection and treatment decisions in affected patients. 103 Recent clinical imaging studies have elucidated type 3 MNV pathophysiology. 104 Three stages are defined based on structural optical coherence tomography (OCT). 105 Precursors to Stage 1 are hyperreflective foci (HRF) at the level of the deep capillary 106 plexus (DCP), often near drusen. Stage 1 includes an intraretinal hyperreflective lesion 107 and cystoid macular edema. In Stage 2, outer retinal disruption appears. At Stage 3, the 108 hyperreflective lesion extends into the sub-RPE basal lamina (BL) space, associated 109 with a pigment epithelium detachment.² By color fundus photography, fluorescein 110 angiography (FA), and OCT, type 3 MNV exhibit a specific regional distribution and 111 pattern of hemorrhage.¹¹⁻¹³ Lesions localize preferentially to the inner ring of the Early 112 Treatment of Diabetic Retinopathy Study (ETDRS) grid. Flame-shaped intraretinal 113 hemorrhages are located over type 3 MNV lesions, pointing toward the fovea. OCT 114 angiography (OCTA) with 3-dimensional reconstruction and display shows vertically 115 oriented components of type 3 MNV. Using this technology, Borelli et al describe two 116 morphologic phenotypes ('filiform' and 'saccular') of advanced type 3 MNV.¹⁴

Intraretinal vascular morphologies in treated AMD

117	Prior clinicopathological correlation has elucidated some of the cellular detail
118	corresponding to the OCT-based stages. ^{15, 16} Neovascular complexes originating at the
119	DCP have a vertical and downward trajectory. These complexes expand posteriorly and
120	cross persistent basal laminar deposit (BLamD) to enter the sub-RPE-BL space. Some
121	complexes appear like base-down pyramids that are ensheathed by collagenous
122	material. ^{3, 16} Participatory cells include macrophages, VEGF-positive fibroblasts,
123	lymphocytes, Müller cell processes, and subducted RPE cells. ^{15, 16} Hence, ischemia and
124	inflammation may promote the development and progression of type 3 MNV. ^{15, 16}
125	Microvascular abnormalities involving the DCP include microaneurysms,
126	telangiectasia, perifoveal exudative anomalous vascular complex (PEVAC), and capillary
127	macroaneurysms. ¹⁷⁻²² PEVAC was initially described in non-AMD eyes as an isolated
128	aneurysmal dilation of a retinal capillary originating between the superficial and deep
129	plexuses, with exudation that is unresponsive to anti-VEGF. ^{17, 22, 23} Deep retinal age-
130	related microvascular anomalies (DRAMA) are recently proposed as DCP alterations in
131	the setting of AMD findings like soft drusen and intraretinal HRF. Eyes with DRAMA
132	show abnormal horizontal or vertical vessels with a diameter of >50 μm and/or a location
133	below the posterior border of the outer plexiform layer (OPL) . ²⁴ In contrast to type 1
134	MNV, ²⁵ precursors, early stages, and potential masqueraders for type 3 MNV, which
135	may include DRAMA, are not described at the histologic level. ²⁶ Human eyes with
136	longitudinal clinical imaging are especially valuable sources for such information. ³
137	Herein we directly compared longitudinal OCT and angiographic signatures of
138	intraretinal neovascularization and microvascular anomalies to corresponding histology.
139	We analyzed both eyes of a single patient who had received intravitreal anti-VEGF
140	treatments for type 3 MNV over the course of 5 years (right eye) and 9 months (left eye).
141	

Intraretinal vascular morphologies in treated AMD

143 Methods

144 Compliance

145 Approval for this study was obtained by Institutional review at the University of

- 146 Alabama at Birmingham (protocol #300004907). The study was conducted in
- 147 accordance with the tenets of the Declaration of Helsinki and the Health Insurance
- 148 Portability and Accountability Act of 1996.^{27, 28}

149 <u>Clinical course</u>

150 A white, pseudophakic woman in her 90's received comprehensive ophthalmologic

151 examination and multimodal imaging during a 5-year follow-up for bilateral type 3 MNV

secondary to AMD. The patient presented 5 years prior to death with exudative type 3

153 MNV in the right eye. Over 5 years, she received a total of 37 intravitreal anti-VEGF

154 injections over approximately 6 fluid resorption cycles in the right eye (12 x 0.5 mg/ 0.05

155 ml ranibizumab then 25 x 2 mg/ 0.05 ml aflibercept). One fluid resorption cycle is defined

as the time in weeks and the number of injections needed from initial detection of

157 intraretinal/ subretinal edema on OCT until complete absence of edema on OCT. The

158 left eye was diagnosed with exudative type 3 MNV 4 years after the right eye. Over 9

159 months, the left eye received a total of 6 intravitreal anti-VEGF injections over

approximately 2 fluid resorption cycles (12 x 0.5 mg/ 0.05 ml ranibizumab). Her general

161 medical history included dyslipidemia and paroxysmal atrial fibrillation. Six months

162 before death, the patient was diagnosed with gallbladder adenocarcinoma. Her last anti-

- 163 VEGF treatment before death due to adenocarcinoma was 3 and 2 months for the left
- 164 and right eye, respectively.

165 <u>Clinical image capture and analysis</u>

166 All images were acquired using Spectralis HRA+OCT (Heidelberg Engineering,

167 Heidelberg, Germany). Available for review were 11 (right eye) and 7 (left eye) eye-

168	tracked spectral domain OCT volumes (6 mm x 6 mm horizontal and radial scans; 20° x
169	20° field). FA was available for both eyes at first presentation and 4 years later.
170	One eye-tracked spectral domain OCTA volume (3 mm x 3 mm horizontal scans,
171	256 B-scans at 6 μm spacing, 10° x 10° field, ART 5, quality 34 dB) was obtained of the
172	right eye 3.5 years after presentation. ²⁹ An investigational version of Heidelberg Eye
173	Explorer (v. 6.16.100.701, Heidelberg Engineering, Heidelberg, Germany) was used for
174	analysis, processing, and post-processing of data. ^{3,30} Projection artifact was removed via
175	3-dimensional vessel-shape estimation and a Gaussian blur filter. ^{3, 30} Raw (floating point)
176	data were exported as a .VOL file. Linear quadratic estimation (noise variance estimate
177	of 0.05 and a gain of 0.8) was applied using a code designed in MATLAB version
178	R2019b (Natick, Massachusetts: The MathWorks Inc.; 2019) to visualize neovascular
179	lesions at different angles of rotation, volume rendering and analysis of processed OCTA
180	data utilized Imaris v9.5 (Bitplane, Andor Technology plc.). ³¹ The Filament Tracer tool
181	was used to trace superficial arteries and veins after evaluation of dye circulation in FA.
182	Video recording and still annotations were annotated to highlight specific details from
183	structural and flow data.
184	Previous reports indicated both eccentricity- and hemifield-dependent
185	asymmetries in the spatial distribution of type 3 MNV. ^{11, 12, 32} Thus, for potential
186	mechanistic insight for tissue-level associations, location of vascular lesions was
187	documented. Lesion distance from the fovea was calculated using the OCT volume and
188	NIR en face image using a custom ImageJ plug-in 'Spectralis Browser OCT', available at
189	https://sites.imagej.net/CreativeComputation/. Meridional position was documented
190	using the sectors of the ETDRS grid. ^{33,34}
191	

Intraretinal vascular morphologies in treated AMD

192 <u>Histology preparation and image analysis</u>

As described. ³⁵ globes were recovered 2:05 hours after death and preserved in 193 194 buffered 1% paraformaldehyde and 2.5% glutaraldehyde. Pre-mortem eye-tracked OCT 195 volumes were registered to post-mortem OCT volumes of the same globes.³⁶ A 196 rectangular tissue block containing fovea and optic nerve was post-fixed in 1% osmium -197 tannic acid – paraphenylenediamine and embedded in epoxy resin. A tissue block 8 mm 198 x12 mm wide was processed for stepped sections at 30-60 µm intervals. Interleaved 30 199 µm-thick slabs were re-embedded for transmission electron microscopy (TEM). Sub-200 micrometer sections stained with toluidine blue were scanned using a 60X oil immersion 201 objective.³⁷ Tissue sections on 112 (right eye) and 87 (left eye) glass slides spanning a 202 distance of 5453 µm (right eye) and 4243 µm (left eye) centered on the two foveas were 203 matched to clinical OCT scans by comparing overall tissue contours. DRAMA vessels are defined by a diameter criterion (>50 µm),²⁴ and our previous 204 205 and current observations indicated that a collagenous sheath surrounds type 3 MNV 206 neovessels. Further, OCTA shows only the moving blood cell column and not the 207 collagenous sheath. Therefore, we manually measured internal (luminal) and external 208 cross-sectional diameters of vessels ('oval' tool, FIJI Is Just: ImageJ 2.0.0-rc- 69/1.52p; 209 www.fiji.sc;). Type 3 MNV vessels meandered over several glass slides, and sections on 210 each slide were measured. To contextualize neovessel measurements, DCP vessels on 211 either side of the area directly involved in exudation in the index case were also 212 measured. Further, vessels aligned along the outer border of the INL of intermediate AMD eves and age-similar controls (n= 8 each) on the Project MACULA website of AMD 213 214 histopathology were also measured.²⁵ Because vessels could run longitudinally within a 215 section, we report a minimal cross-section diameter (approximated by Feret diameter in 216 ImageJ for ellipses). Due to small numbers, these data were not analyzed statistically.

Intraretinal vascular morphologies in treated AMD

218 **Results**

- 219 **Table S1** lists all figures to provide an overview of all imaging data pieces.
- 220 Classification of lesions and longitudinal clinical imaging
- 221 We first classify vascular complexes in the two eyes at one time point then
- describe them in longitudinal clinical imaging and detailed histology. Table 2 lists
- hyperfluorescent lesions seen by FA 11 months before death (Figure 1). Six of 7 lesions
- localized to the inner ring of the ETDRS grid (0.5-1.5 mm eccentricity), with the seventh
- at 1.52 mm. There was no predilection for any one sector. Six of 7 lesions were
- confirmed as vascular by histology, and the seventh (Figure S2) could not be found.
- 227 Lesion morphology was categorized as tangled type 3 MNV (n=1), pyramidal type 3
- 228 MNV (n=2), or DRAMA (n=3). As seen previously, ^{3, 16} pyramidal type 3 MNV was
- 229 defined as a focal, vertically extending neovessel complex. Tangled type 3 MNV was
- 230 defined as a horizontally extending neovessel complex. DRAMA was defined as
- anomalous vascular elements extending posterior to the DCP and into the HFL/ONL, i.e.,
- anterior to the ELM.²⁴ Hyperfluorescent lesions in the right eye due to window defects
- 233 were reported elsewhere.³⁸
- At initial presentation 5 years before death, the right eye exhibited multiple instances of MNV secondary to AMD with multifocal leakage on FA (**Figure S3**). At this time, fluid was not detected in the left eye (**Figure S4**). Four years later and 11 months before death (**Figure 1**), the left eye was diagnosed with exudative type 3 MNV due to AMD. By this time, the right eye had received 32 intravitreal anti-VEGF injections at intervals of 4-8 weeks resulting in 4 fluid resorption cycles.
- 240 Pyramidal (OD 2, OS 4) and tangled (OD 1) type 3 MNV

241 Pyramidal type 3 MNV (OS 4) closely resembles previously described OD 2⁴ in

- terms of location, OCT appearance, and histologic features (Figure 1, Figure 5, Figure
- 6, respectively). In brief, OS 4 is a vertically oriented, pyramidal-shaped, intraretinal

Intraretinal vascular morphologies in treated AMD

244	lesion located in the nasal sector of the ETDRS inner ring, with heterogeneous
245	hyperreflectivity on OCT (Figure 5). On histology, this lesion corresponds to a collagen-
246	ensheathed neovascular complex that extends from the OPL/INL border through the
247	HFL /ONL (Figure 6A). The complex is flanked by RPE cells that extend off the top of
248	the pyramid and along a DCP vessel (Figure 6B). The pyramid base adheres to
249	denuded and persistent BLamD, which drapes a calcified druse (Figure 6A&B). ⁴ The
250	vessel did not enter the subRPE-BL space, and no choroidal contribution was found.
251	Transmission electron microscopy of this pyramidal lesion reveals endothelial
252	cells and pericytes (Figure 7A). Endothelial cells are not fenestrated (Figure 7B), like
253	endothelial cells of the DCP and unlike endothelial cells of the choriocapillaris (Figure
254	7C&D). Other vessel wall components, e.g., smooth muscle cells, connective tissue, or a
255	3-layer arterial configuration, cannot be identified. In RPE cells arrayed along the sloping
256	sides of the calcified druse, lipofuscin becomes less electron-dense, smaller, and less
257	tightly packed (Figure 7E), in a smooth transition. These findings suggest
258	transdifferentiation, rather than ingestion of RPE organelles by invading phagocytes.
259	Next we consider tangled type 3 MNV (OD 1), for which en face OCTA (Figure
260	8A2) and OCT with flow overlay (Figure 8A3) shows persistent flow signal. Over time,
261	the extent of intraretinal fluid surrounding OD 1 in the INL and HFL fluctuates (Figure
262	8B2, Figure 8C2, respectively). Volume rendering of structural OCT and OCTA together
263	highlights flow within a hyperreflective lesion at the ONL and bacillary layer (Figure 9A,
264	Video S1). Inflow and outflow vessels can be connected to a superficial artery and vein,
265	respectively (Figure 9B&C). The RPE/BrM complex below the lesion is split by
266	hyporeflective material producing a double layer sign (Figure 7B2). ³⁹ Numerous HRF
267	are present in the INL (Figure 8C2).
268	Histologic analysis reveals components of tangled type 3 MNV (OD 1, Figure
• • •	

269 **8D**). Magnified histology shows a vascular complex spanning 249 μm horizontally,

Page 11 of 33

270	extending into the superior perifovea (Figure S10). The complex is partly ensheathed by
271	collagenous material and flanked by intraretinal RPE cells. The INL/OPL border
272	subsides where the vascular lesion extends through the HFL/ONL (Figure S10C). The
273	ELM subsides at both edges of the calcified druse (yellow arrows in Figure S10B).
274	Bruch's membrane appears intact without evidence of a choroidal contribution to the
275	MNV lesions, or evidence of MNV contributing to the OCT double layer sign (Figure
276	S10A-C). Neovessels within the INL are moderately dilated, suggesting drainage
277	venules (Figure S10A). ⁴⁰
278	To summarize, vascular geometry and thickness of the collagenous sheath
279	differentiates tangled versus pyramidal type 3 MNV. The sheath surrounding the tangled
280	complex is thin (Figure S10), and that surrounding pyramidal type 3 MNV is thick
281	(Figure 6). Otherwise, the two subtypes are comparable.
282	DRAMA, in the setting of anti-VEGF therapy
283	As shown below, all three instances of DRAMA (OS 1, OS 3, and OD 3) exhibit
284	mild hyperfluorescence on venous and recirculation phase FA 11 months before death.
285	In histology, all three localize above a horizontal ELM, signifying lack of atrophy.
286	OS 1 includes a vessel extending from the INL into the ONL (Figure 11A). Like
287	type 3 MNV lesions, this DRAMA lesion is located above a soft druse with BLamD and
288	altered RPE at its apex (Figure 11C). Unlike type 3 MNV, OS 1 does not have a
289	collagenous sheath, and the OPL does not subside (Figure 11C2).
290	Corresponding to FA, OCT of OS 3 shows an intraretinal hyperreflective,
291	stacked lesion, without intraretinal cysts (Figure 12A). Over time, a plume of HRF
292	extends nasally, still without evidence of cysts (Figure 12C).41,42 In histology, an RPE
293	tower atop a soft druse extends into the OPL (Figure 12D). This RPE complex
294	surrounds like a gripping hand a vessel extending downward from the DCP (Figure
295	13A&B). By light microscopy, the extending vessel in OS 3 resembles DRAMA OS 1 Page 12 of 33

296	(Figure 11) in its location above a soft druse with thick BLamD and a thinned RPE layer.
297	By transmission electron microscopy, OS 3 (Figure S14) resembles type 3 MNV lesions
298	but lacks a collagenous sheath. Endothelial cells in OS 3 lack fenestrations (Figure 13C),
299	like endothelial cells of the DCP and unlike endothelial cells of the choriocapillaris
300	(Figure 13D&E) Other vessel wall components cannot be identified. The RPE complex
301	is multicellular, with some multinucleated cells (Figure S14). Organelle packing and
302	electron density is similar to in-layer RPE cells (not shown).
303	OCTA flow overlay of DRAMA OD 3 shows an intraretinal hyperreflective lesion
304	containing a pair of vascular outpouchings (Figure 15C). Corresponding histology
305	displays a pair of deeply descending vessels without significant intraretinal fluid (Figure
306	15D). Like type 3 MNV, the vessel complex of this DRAMA is ensheathed by a thin layer
307	of collagenous material and dives from the INL into the HFL (Figure 16A). Unlike type 3
308	MNV, the vessels do not extend past the HFL, and there is no subsidence of the ELM.
309	RPE organelles appear near the vessel complex (Figure 16B).
310	Vessel diameters of vascular lesions and comparison vessels
311	Table S3 shows internal and external vessel diameters of type 3 MNV and
312	DRAMA, as well as DCP vessels in the index case and donor eyes (8 intermediate AMD,
313	83.4 \pm 11.6 years; 8 controls, 84.1 \pm 6.7 years). Five of the 6 index case lesions are
314	noticeably larger (2.5-3-fold) than the comparison vessels. External vessel diameters of
315	type 3 MNV (OD 1, OD 2, OS 4 15.02 μm ± 3.81 μm ; 21.35 μm ± 10.79 μm ; 12.46 μm ±
316	0.95 $\mu m,$ respectively) are larger than nearby DCP diameters (7.18 μm ± 1.11 $\mu m).$ They
317	are also larger than vessel diameters in intermediate AMD (6.79 μm ± 1.05 $\mu m)$ and
318	controls (7.86 μ m ± 1.47 μ m, Table S3A). In DRAMA, external vessel diameters of OS 1
319	and OS 3 (13.39 μm ± 2.68 $\mu m;$ 17.97 μm ± 1.08 $\mu m)$ are considerably larger than the
320	comparison vessels. A similar pattern is seen for internal vessel diameters (Table S3B).

Intraretinal vascular morphologies in treated AMD

- 321 An overview of unifying and distinguishing features of type 3 MNV and DRAMA,
- 322 combining this and prior reports, is provided in **Table 4**.^{3, 16, 24}

323

Intraretinal vascular morphologies in treated AMD

325 **Discussion**

326 In two anti-VEGF treated eves of a single patient with multifocal intraretinal 327 neovascular AMD, we compare longitudinal multimodal clinical imaging and histology of 328 type 3 MNV and DRAMA (Table 2, Table 4). Although one patient, clinical and imaging 329 characteristics are typical of multifocal type 3 MNV, which is frequently bilateral (55%).⁴³ 330 Moreover, the presence of multifocal intraretinal lesions without any type 1 MNV highlights the clinical and pathophysiologic differences between types 3 and 1 MNV.^{11-13,} 331 ^{43, 44} Type 3 MNV is distinguished by intraretinal origin,^{1, 2, 45} high frequency of near-term 332 333 bilateral involvement.⁷⁻⁹ and significant choroidal thinning with reduced perfusion.^{46, 47} 334 Patients with type 3 MNV are older at initial diagnosis than patients with choroidaloriginating MNV, and mostly do not have such vascular lesions themselves.^{11, 12, 44} 335 336 In our case, treated type 3 MNV has two morphologic phenotypes, pyramidal (OD 337 2, OS 4) or tangled (OD 1). All three analyzed complexes originate at the DCP and 338 extend posteriorly to approach persistent BLamD but do not enter the sub-RPE-BL 339 space or cross BrM. These two phenotypes may correspond to those seen by Borelli et 340 al in treatment-naïve type 3 MNV eyes with rotational three-dimensional OCTA. These 341 authors describe 26 lesions as 'filiform' and 9 lesions as 'saccular', which appear similar 342 in shape to pyramidal (filiform) and tangled (saccular).¹⁴ Similarly, in our patient, we find 343 more pyramidal lesions than tangled. It remains to be determined if saccular and filiform 344 lesions differ in spatial distribution and time of onset.¹⁴

Our previous description of pyramidal Type 3 MNV included endothelial cells in a thick collagenous matrix and dysmorphic RPE cells scattered along the neovascular stalk. ¹⁶ The two instances in this case (OD2 and OS4)³ add pericytes plus a nearly continuous covering by highly pigmented RPE (OS4). These data support the early involvement of migratory RPE in type 3 MNV.^{2, 48} The presence of the sheath distinguishes lesions from unaffected DCP vessels. The main differences between

Page 15 of 33

351	pyramidal and tangled lesions are the larger horizontal extent and thinner collagenous
352	sheath of tangled. ³ Endothelial cells of tangled vessels, and presumably also those in
353	pyramidal, lack fenestrations like the source vessels in the DCP.
354	As before, ¹⁶ we did not see vessels of choroidal origin in the sub-RPE space, as
355	reported for advanced type 3 MNV in histopathology and clinic patients. ^{14, 43, 49-51} Nor did
356	we see DCP-originating vessels penetrate through BLamD and enter the sub-RPE- BL
357	space. This level of activation is suggested as necessary for exudation, based on OCTA
358	imaging without projection artifact removal to reduce spurious signal directly under type
359	3 MNV. ⁵² Using volumetric artifact removal, we did not see OCTA flow signal in the sub-
360	RPE-BL space (Figure 8). It is possible that anti-VEGF treatment rendered invisible
361	downward projections from the DCP or upward projections from the choriocapillaris. We
362	think this is unlikely, because neo-capillaries may shrink after treatment, but they do not
363	disappear.53, 54 Our use of stepped epoxy-resin sections for high-resolution microscopy
364	over large areas may miss key details. Nevertheless, in all analyzed sections of this
365	case, both BLamD and Bruch's membrane were intact. Longitudinal imaging before
366	exudation onset would be helpful in understanding this phase of type 3 MNV
367	progression.
368	The thick collagenous sheath of pyramidal type 3 MNV lesions may have
369	implications for clinical monitoring, as follows. All type 3 MNV lesions responded to anti-
370	VEGF with temporary resolution of exudation and persistence over several fluid
371	absorption cycles. By OCTA, some early-stage type 3 MNV lesions appear to completely
372	regress while treatment of later-stage type 3 MNV require continuing therapy. ^{2, 51} Further,

- 373 type 3 MNV can recur after becoming undetectable on OCTA during treatment. ^{52, 55}
- 374 Lesions with thick sheaths remain detectable by structural OCT long after treatment.⁵⁴
- 375 While the role of basement membranes is well established for vascular endothelial

376	cells, ⁵⁶⁻⁵⁸ the role of a perivascular collagenous sheath is still being learned. However,
377	we can speculate that the collagenous sheath structurally stabilizes the endothelial cells
378	within it. It is possible that both VEGF and anti-VEGF agents impact lesions with sheaths
379	principally where the sheath is absent. On transmission electron microscopy, the
380	collagenous neovascular stalk was populated by endothelial cells and pericytes that
381	either remained, self-renewed, or migrated in during cycles of varying VEGF level. MNV
382	persistence after treatment, as well as recurrence after apparent regression, may be due
383	to thick collagenous sheaths surrounding vessel walls. If so, then type 3 MNV might
384	require monitoring for disease activity by vascular characteristics in addition to fluid.
385	We showed that type 3 MNV can coexist with vascular formations that are
386	candidate precursors, early stages, and masqueraders for type 3 MNV. All three
387	DRAMA originated from the DCP within the inner ring of ETDRS and extended
388	posteriorly into the HFL. None of the DRAMA lesions involved the superficial capillary
389	plexus, and no significant intraretinal fluid was detectable on OCT over time. Like
390	pyramidal type 3 MNV (Figure 10), one DRAMA examined by electron microscopy had
391	non-fenestrated endothelial cells and pericytes (Figure S14). Unlike type 3MNV and like
392	native DCP, two DRAMA lacked a collagenous sheath. The one DRAMA with a thin
393	sheath (OD 3) also extended furthest of the three into the ONL, perhaps indicating
394	chronicity. Importantly, none of the DRAMA were accompanied by descent of the ELM,
395	the border of atrophy in neurosensory retina, although the ELM can be perforated by
396	inwardly migrating RPE as in OS 3. It is unlikely that DRAMA in our case represent
397	exudative or non-exudative perifoveal vascular anomalous complexes (ePVAC/
398	nePEVAC), ^{31,35,36} which typically appear above the DCP. Microvascular anomalies in
399	eyes with neovascular and non-neovascular AMD include capillary dilations and
400	telangiectasia that are associated with locally increased VEGF expression. $^{17,59-61}$ A
401	recent study showed that 19/94 eyes with type 3 MNV exhibited an asymptomatic Page 17 of 33

402	precursor stage on OCT. ⁴³ It is possible that lack of exudation and non-progression to
403	type 3 MNV in our case might result from VEGF suppression. ⁶² Longitudinal imaging is
404	required to definitively place DRAMA in the progression sequence of type 3 MNV.
405	All analyzed vessels localized within 500-1500 μm of the foveal center, aligned
406	with similar findings for solitary and multifocal type 3 MNV. ^{11, 12} A role for choroidal
407	ischemia is hypothesized, $^{11, 63-65}$ because the choroid is thinner in eyes with type 3 MNV
408	than in eyes with types 1 and 2 MNV.66,67 The radial symmetry of lesions around and
409	close to the fovea further suggests an association with the distribution of photoreceptors
410	and their support cells, which vary markedly in this site. The ETDRS inner ring of type 3
411	MNV vulnerability is just peripheral to the foveal avascular zone ³² on the inner slope of
412	the crest of high rod density. Rod vision in AMD eyes is poorest in this inner ring. 68-72
413	Metabolic demand of foveal cones is very high, and choriocapillaris OCTA signal
414	decreases under the fovea throughout adulthood.73,74 It is thus possible that the
415	distribution of type 3 MNV is an additional effect of microvascular changes under the
416	fovea that also contribute to high-risk drusen and reduced sustenance of nearby rods.
417	Study strengths include the availability of OCTA with eye-tracked OCT,
418	volumetric projection artifact removal, rapid tissue preservation to maintain retinal
419	attachment, registration of pre-mortem and post-mortem OCT volumes, and
420	comprehensive histologic and microscopy techniques to reveal vessels and perivascular
421	tissue elements. Limitations include the lack of longitudinal OCTA imaging 9,75 and lack
422	of color fundus photography to reveal discoloration patterns typical of type 3 MNV. ¹⁴
423	Limitations to the laboratory study included use of stepped sections, lack of electron
424	microscopy for all lesions, and lack of immunohistochemistry to support cell type
425	identifications based on morphologic criteria. Finally, observations from one patient
426	however detailed cannot elucidate the full range of biologic variability.

- 427 Nevertheless, our study helped define morphologies of type 3 MNV and offered
- 428 candidate precursors that might guide diagnosis and disease monitoring in the future.
- 429 The presence and extent of a collagenous sheath distinguishes type 3MNV from normal
- 430 DCP vessels and may represent a stage in the evolution of DRAMA toward type 3MNV.
- 431 The hypotheses offered herein can be tested in the larger samples available in clinic
- 432 populations and clinical trial imaging datasets, ideally before onset of exudation.
- 433

Intraretinal vascular morphologies in treated AMD

434 Acknowledgments

435

436 **Contribution statement**

- 437 All authors were involved in drafting the article or revising it critically for important
- 438 intellectual content, and all authors approved the final version to be published. Dr. Curcio
- 439 and Dr. Berlin had full access to all the data in the clinical picture and take responsibility
- 440 for the integrity of the data and the accuracy of the data analysis. Study conception and
- 441 design: AB, DC, LC, CB, RM, DF, KBF, CC. Acquisition of data: RM, CB, JM, LC, AB,
- 442 DC, KBF, CC. Analysis and interpretation of data: AB, DC, LC, DF, KBF, CC. Writing of
- 443 manuscript: AB, DC, CB, LC, RM, DF, KBF, CC.
- 444

445 **Financial support**

446 This work was supported by Genentech/ Hoffman LaRoche, The Macula Foundation, 447 Inc., New York, NY; unrestricted funds to the Department of Ophthalmology and Visual 448 Sciences (UAB) from Research to Prevent Blindness, Inc., and EyeSight Foundation of 449 Alabama. AB reports grants from the Dr. Werner Jackstädt-foundation. DC was 450 supported in part by a studentship from Fundação Luso-Americana para o 451 desenvolvimento (FLAD, USA R&D@PhD - Proj 2020/0140). Purchase of the slide 452 scanner was made possible by the Carl G. and Pauline Buck Trust. 453 The sponsors had no role in the design and conduct of the study: collection. 454 management, analysis, and interpretation of the data; preparation, review, or approval of

the manuscript; and decision to submit the manuscript for publication.

Intraretinal vascular morphologies in treated AMD

457 Financial disclosure

- 458 KBF is a consultant to Genentech, Zeiss, Heidelberg Engineering, Allergan, Bayer, and
- 459 Novartis. CAC receives research funds from Regeneron (outside this project). DF is an
- 460 employee of Genentech and a stockholder of Roche.
- 461

462 **Meeting presentation**

- 463 This work was submitted as part of an abstract to the annual meeting of The Association
- 464 for Research in Vision & Ophthalmology (ARVO) May 2021 and May 2022.
- 465
- 466
- 467
- 468
- 469

Intraretinal vascular morphologies in treated AMD

470 Figures

471 Figure 1. Multimodal retinal imaging of both eyes, 11 months before death.

- 472 **A** & **D**. Fluorescein angiography (FA) in venous (**A**) and recirculation phases (**D**) shows
- 473 multiple instances of hyperfluorescence. Vessels were found by histology at the green,
- 474 yellow, and fuchsia arrowheads in the right (**A**), and left eye (**D**). At the white arrowhead
- in the left eye, no vessel could be found in histology.
- 476 **B** & **E**. Near-infrared reflectance imaging (NIR) shows reduced reflectance in areas of
- 477 angiographic leakage (arrowheads), possibly due to retinal edema. Soft drusen exhibit
- 478 hypo- and hyperreflective mottling. Scale bar 200 μ m.
- 479 **C** & **F**. Fundus autofluorescence (FAF; λ_{ex} = 488 nm) highlights subretinal drusenoid
- 480 deposits especially superior to the fovea.
- 481 Lesion number, type, and spatial distribution are listed in **Table 2**.
- 482

483 Figure S2. <u>Hyperfluorescence without histologic correlate</u>, OS 2

- 484 **A**. Fluorescein angiography (FA, **A1**) venous phase, 11 months before death, shows
- 485 multiple instances of hyperfluorescence. An optical coherence tomography (OCT) B-
- 486 scan (green line) displays drusen, a double-layer sign (white arrowhead), choroidal
- 487 hypertransmission, and hyperreflective foci (A2).
- 488 **B, C**. At 4 and 2 months before death, with 5 (**B**) and 6 (**C**) total injections, respectively,
- 489 the lesion is stable, without intraretinal cysts.
- 490

491 Figure S3. Initial presentation of right eye, 5 years before death

- 492 **A-E**. Fluorescein angiography (FA), near infrared reflectance images (NIR), and radial
- 493 optical coherence tomography (OCT) B-scans show exudative age-related macular
- degeneration in the right eye at initial presentation. Based on these findings anti-VEGFtherapy is initiated.
- 496 **A**. FA recirculation phase shows marked leakage. Corresponding OCT shows
- 497 intraretinal and subretinal hyporeflective cysts and spaces representing exudation,
- 498 located above drusenoid pigment epithelium detachments in the fovea and parafovea.
- 499 **B**. NIR and OCT show hyporeflective subretinal drusenoid deposits and hyperreflective
- 500 soft drusen across the macula. Hyperreflective foci are present in inner and outer
- 501 nuclear layer.
- 502

Intraretinal vascular morphologies in treated AMD

503 Figure S4. Initial presentation of left eye, 5 years before death

- 504 **A-E**. Near infrared reflectance images (NIR) and radial optical coherence tomography
- 505 (OCT) B-scans show non-exudative age-related macular degeneration in the left eye.
- 506 Hyporeflective subretinal drusenoid deposits and hyperreflective soft drusen (**B** teal and
- 507 fuchsia arrowheads respectively) appear across the macula.
- 508 **B**. On the recirculation phase of fluorescein angiography (FA), no intraretinal or
- 509 subretinal fluid or leakage is present, ensuring absence of active MNV exudation.
- 510 **F**. A shallow RPE elevation with choroidal hypertransmission (white arrowhead) and
- 511 hyperreflective focus was stable on longitudinal follow-up by OCT (Figure S4). No
- 512 vessel was found in histology. This lesion presumably corresponds to a calcified druse.³⁸
- 513

514 Figure 5. Multimodal imaging, clinical course, and histology of pyramidal type 3

- 515 **MNV, OS 4.**
- 516 **A**. Venous phase fluorescein angiography (FA, **A1**) shows mild leakage at site of type 3
- 517 MNV 11 months before death. Green lines on FA represent optical coherence
- 518 tomography (OCT) B-scans. Horizontal OCT B-scan (A2) displays a hyperreflective
- 519 lesion, hyperreflective foci (HRF), and small intraretinal cysts.
- 520 **B**. Blue lines on near-infrared reflectance (NIR, **B1**), represents histology section in **D**.
- 521 Radial OCT B-scan (B2) displays enlarged intraretinal cysts, after 5 total injections and 8
- 522 weeks following the prior injection. There is also subsidence of the outer plexiform layer
- 523 (OPL) and external limiting membrane (ELM).
- 524 **C**. On radial OCT B-scan (**C2**), intraretinal fluid is reduced after 6 injections and 6 weeks
- 525 following the prior injection. Numerous HRF are present in the inner nuclear layer (INL;
- 526 **C2**; scale bar 200 μm).
- 527 **D**. On histology, type 3 MNV is a pyramidal complex bounded by retinal pigment
- 528 epithelium cells. It extends from the INL/ OPL border to basal laminar deposit draping a
- 529 calcified druse. Structural damage to Henle's fiber layer at the right of the panel (green
- asterisk) may indicate an area of prior intraretinal fluid. Magnified histology is shown in
- 531 Figure 6. Scale bar 100 µm.
- 532 Blue line, histology section. Time in months, time before death.

Intraretinal vascular morphologies in treated AMD

534 Figure 6. Pyramidal vascular complex in type 3 MNV, OS 4.

- 535 **A, B**. A pyramidal complex includes neovessels ensheathed by thick layers of
- 536 collagenous material and flanked by retinal pigment epithelium cells. The complex
- 537 extends from the inner nuclear layer (INL) through the outer plexiform layer, Henle fiber
- 538 layer, outer nuclear layer (OPL, HFL, ONL, respectively) and terminates at the basal
- 539 laminar deposits draping a calcified druse. Bruch's membrane appears intact with no
- 540 evidence of a choroidal contribution to the neovessel complex. The external limiting
- 541 membrane (ELM) descends at both sides of type 3 MNV base. There is some fluid at the
- 542 OPL-HFL border (yellow asterisk in **B**). Areas within dotted green boxes are shown in
- 543 **Figure 10**.
- 544

545 Figure 7. Transmission electron microscopy of pyramidal type 3 MNV, OS 4.

- 546 See Figure 8 for light microscopy of OS4. **A**. Neovessel with erythrocyte in the lumen
- 547 (blue asterisk) is ensheathed by endothelium, pericyte, and collagenous material (purple,
- 548 white, and black asterisks, respectively). Surrounding retinal pigment epithelium (RPE)
- 549 cells merge into multi-nucleated cells (red asterisk) or disperse into the Henle fiber layer
- 550 (HFL, green asterisk). Phagolysosomes are not visible in the RPE cells.
- 551 **B-D**. Endothelial cells in the neovessel and comparison vessels are displayed. The
- 552 lumen is located at the bottom of all panels.
- 553 **B**. No fenestrations are detected in the neovessel (orange arrowheads).
- 554 **C**. Fenestrations are visible in the choriocapillaris (orange arrowheads).
- 555 **D**. No fenestrations are detected in the deep capillary plexus (orange arrowheads).
- 556 E. Atop the calcified druse (fuchsia asterisk), RPE lipofuscin is more electron-dense at
- the druse base than at the druse top (left vs right in the panel). These changes are
- 558 consistent with transdifferentiation.
- 559

Figure 8. Multimodal imaging, clinical course, and histology of tangled type 3MNV, OD 1.

- 563 **A.** Green and red lines on near-infrared reflectance (NIR, A1) represent optical
- 564 coherence tomography (OCT) B-scans corresponding to en face OCT angiography
- 565 (OCTA, A2) and OCT B-scan with flow signal overlay (A3). After 29 total injections and 8
- 566 weeks following the prior injection (A2&A3), flow signal persists within the tangled
- 567 hyperreflective type 3 MNV lesion (green arrowhead). The RPE/Bruch's membrane

Intraretinal vascular morphologies in treated AMD

- 568 complex is split by hyporeflective material and appears as a "double layer" sign without 569 flow signal (A3). Red lines in A2 indicate the segmentation boundaries [outer plexiform 570 layer (OPL)-retinal pigment epithelium (RPE)] used to create the en face OCTA (A2). 571 B. Fluorescein angiography (FA, B1) shows late venous phase hyperfluorescence, after 572 32 total injections and 8 weeks following the last injection. OCT B-scan (B2) shows 573 intraretinal fluid in the inner nuclear and Henle fiber layers surrounding the type 3 MNV 574 lesion (green arrowhead). 575 C. NIR (C1) and radially oriented OCT B-scan (C2) shows intraretinal fluid adjacent to 576 the tangled type 3 MNV lesion (green arrowhead), after 36 total injections and 8 weeks 577 following the prior injection. Blue line in C1 represents histology section in panel D. 578 D. Panoramic histology shows a horizontally oriented tangled type 3 MNV lesion (green 579 arrowhead), partly bounded by RPE cells (scale bar 200 µm). The complex extends from 580 the inner nuclear layer border to a calcified druse, which correlates to the double layer 581 sign in B1. The druse is draped by basal laminar deposit and lacks RPE at its apex. 582 Time in months, time before death; BCVA, best corrected visual acuity. 583 584 Figure 9. Volume rendering of structural optical coherence tomography (OCT, 585 gray) and OCT angiography (OCTA, yellow) of tangled type 3 MNV, OD 1. 586 **A**. Neovascular blood flow within a hyperreflective structure (white arrowheads) is 587 observed at the level of the outer nuclear layer (ONL). 588 B. Three-dimensional analysis of neovascular blood flow depict an anastomosis above 589 the retinal pigment epithelium (RPE)/ Bruch's membrane (BrM: green section) and a 590 tangled structure connecting to the superficial artery (red arrow) and vein (blue arrow).
- 591 **C**. Volume rendering of OCTA with orthogonal structural sections evidence a tangled
- 592 neovascular lesion.
- 593

594 Figure S10. Tangled vascular complex in type 3 MNV, OD 1.

- 595 A-C. Tangled vascular complex (fuchsia arrowheads indicate lumen) spans 249 µm
- 596 horizontally towards the superior perifovea (**A**, 759 μm from fovea; **B**, 719 μm from fovea;
- 597 **C**, 552 µm from fovea). The complex is partly ensheathed by collagenous material and is
- 598 flanked by retinal pigment epithelium (RPE) cells. Two cells rest entirely within the outer
- 599 plexiform layer (OPL)/ inner nuclear layer (INL; light blue arrowhead in A). The INL/OPL
- 600 subsides, and the vascular complex extends from the INL/OPL border through the Henle
- 601 fiber layer (HFL)/ outer nuclear layer (ONL). The complex adheres to basal laminar

Intraretinal vascular morphologies in treated AMD

- 602 deposits (BLamD) draping a calcified druse (d). Bruch's membrane (BrM) appears intact
- 603 without evidence of a choroidal contribution. The external limiting membrane (ELM)
- 604 descends at both edges of the calcified druse (yellow arrowheads in **B**). Vessel walls do
- 605 not exhibit obvious arterial or venous features. Vessel diameter within the INL was larger
- 606 than 15 µm, suggesting drainage venules.
- 607

608 Figure 11. Deep retinal age-related microvascular anomaly (DRAMA), OS1.

- 609 **A.** Near infrared reflectance (NIR) shows drusen and subretinal drusenoid deposits 11
- 610 months before death. Blue line, plane of histology section.
- 611 **B**. Fluorescein angiography (FA) recirculation phase shows minimal leakage at the site 612 of DRAMA.
- 613 **C.** On histology, a vessel extends downwards (yellow arrowheads) from the inner
- 614 nuclear layer (INL) into the outer plexiform layer (OPL) above a druse.
- 615

616 Figure 12. Multimodal imaging and histology of deep retinal age-related

- 617 microvascular anomaly (DRAMA) with intraretinal RPE complex, OS 3.
- 618
- 619 A. Fluorescein angiography (FA) venous phase shows faint staining, 11 months before
- 620 death (A1). Optical coherence tomography (OCT, A2) shows a stack of intraretinal
- 621 hyperreflective foci (HRF, fuchsia arrowhead). No intraretinal cysts are visible.
- 622 **B.** After 6 total injections and 6 weeks following the prior injection, the stacked lesion
- 623 (fuchsia arrowhead) is stable, without cysts. A plume of HRF extend nasally 2 months
- before death. Green lines, OCT B-scans; blue line, histology section.
- 625 **C.** On histology, a retinal pigment epithelium tower (fuchsia arrowhead) rises upward
- 626 from a soft druse. Cells surround a vessel and extend into the outer plexiform layer.
- 627 Magnified histology is shown in **Figure 13**.
- 628

629 Figure 13. RPE complex associated with deep retinal age-related microvascular

- 630 anomaly (DRAMA), OS 3.
- 631 **A**. A "hand" shaped complex consisting of retinal pigment epithelium (RPE) cells
- 632 surrounds vessel extending downward from the deep capillary plexus. Electron
- 633 microscopy of the area in the dotted fuchsia box is shown in **Figure S14**.
- 634 **B**. The RPE complex extends upward to the inner nuclear layer (INL). On either side of
- 635 this complex, there is no subsidence of outer plexiform layer (OPL) or external limiting

Intraretinal vascular morphologies in treated AMD

- 636 membrane (ELM), and the outer nuclear layer (ONL) is thinned. The complex emanates
- 637 from a continuous RPE layer over basal laminar deposit (BLamD) and a soft druse. The
- 638 druse is artifactually detached from Bruch's membrane (BrM).
- 639 **C-E**. Endothelial cell (EC) ultrastructure in DRAMA and comparison vessels are shown.
- 640 Vascular lumen is at the bottom of all panels.
- 641 **C.** No fenestrations are visible in the DRAMA (red blood cell, RBC).
- 642 **D.** No fenestrations are visible in the deep capillary plexus (pericyte, P).
- 643 **E.** Fenestrations are visible in the choriocapillaris endothelium (orange arrowheads;
- 644 white blood cell, WBC).
- 645

646 Figure S14. Transmission electron microscopy of DRAMA with RPE complex, OS

- 647 **3.**
- 648 The Vessel is ensheathed by an endothelial (E) cell and a pericyte (P), with little
- 649 collagen. The Lumen contains a leukocyte (LC) and a red blood cell (RBC). The
- 650 surrounding tower of retinal pigment epithelium (RPE) is multicellular (white asterisk),
- and multinucleated (fuchsia asterisks). RPE organelle packing density and electron-
- density is similar to in-layer RPE cells (not shown).
- 653

Figure 15. Multimodal imaging of deep retinal age-related microvascular

- 655 anomalies (DRAMAs), OD 3.
- 656 **A.** Fluorescein angiography (FA) venous phase shows mild hyperfluorescence 11
- months before death. **B**. Green and blue lines on near-infrared reflectance (NIR),
- represent optical coherence tomography (OCT) B-scan (C) and histology section (D). C.
- 659 Horizontally oriented OCT B-scan with OCT angiography (OCTA) flow overlay shows
- 660 cyst-like spaces in the Henle fiber layer adjacent to a pair of hyperreflective DRAMAs
- 661 (fuchsia arrowheads). The retinal pigment epithelium/Bruch's membrane complex to the
- 662 left is split by hyporeflective material. **D**. OCTA shows a pair of intraretinal flow signals
- 663 (fuchsia arrowheads). E. Histology shows a pair of vessels extending from the inner
- nuclear layer border to the outer nuclear layer. Magnified histology is shown in Figure
- 665 **16**.
- 666

- **Figure 16. Vascular complex of deep retinal age-related microvascular anomaly**
- 668 (DRAMA), OD 3.
- 669
- 670 A, B. A penetrating pair of vessels, (DRAMAs, fuchsia arrowheads) ensheathed by
- 671 collagenous material dives from the inner nuclear layer (INL) into the Henle fiber layer
- 672 (HFL)/outer nuclear layer (ONL). Next to the vessels is a degenerative cyst in the Henle
- 673 fiber layer (HFL). There is no subsidence of external limiting membrane (ELM). The ONL
- 674 is thinned.
- 675 **C**. Retinal pigment epithelium (RPE) from the edge of a druse (d) migrates towards the
- 676 lower edge of the vessel complex, right side.

677 Supplementary Video

678

679 Video S1.

680

681 Volume rendering of structural OCT (gray) and OCTA (yellow) of tangled type 3 MNV, OD 1 (Fig. 5).

The cube is rotated 180° to highlight vascular findings in the superior macula region. Coronal view demonstrates blood flow

immediately below the deep capillary plexus level in two separate areas. Superposition with structural OCT (gray channel)

demonstrates neovascular blood flow within an hyperreflective structure at the outer nuclear layer and above Bruch's membrane

(BrM). The superficial arteries (red) and veins (blue) in the vicinity of the lesion are outlined after fluorescein angiography analysis.
Three-dimensional analysis of neovascular blood flow depicts an anastomosis right above BrM (green section) Spinning around the

687 neovascular blood-flow highlights separate inflow and outflow.

688

689

Intraretinal vascular morphologies in treated AMD

References

- 1. Freund KB, Zweifel SA, Engelbert M. Do we need a new classification for choroidal neovascularization in age-related macular degeneration?, Retina. 2010;30(9):1333-49.
- 2. Su D, Lin S, Phasukkijwatana N, et al. An updated staging system of type 3 neovascularization using spectral domain optical coherence tomography. Retina 2016;36:S40-S9.
- 3. Berlin A, Cabral D, Chen L, et al. Correlation of Optical Coherence Tomography Angiography of Type 3 Macular Neovascularization With Corresponding Histology. JAMA Ophthalmol. 2022;140(6):628-633.
- 4. Spaide RF, Jaffe GJ, Sarraf D, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology 2020;127(5):616-36.
- 5. Yannuzzi LA, Negrão S, Tomohiro I, et al. Retinal angiomatous proliferation in agerelated macular degeneration. Retina 2012;32:416-34.
- 6. Jung JJ, Chen CY, Mrejen S, et al. The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration. American Journal of Ophthalmology 2014;158(4):769-79. e2.
- 7. Kim JH, Kim JW, Kim CG, Lee DW. Influence of fellow-eye examination interval on visual acuity at fellow-eye neovascularization in unilateral type 3 neovascularization. Retina 2020;40(7):1255-61.
- 8. Kwak JH, Park WK, Kim RY, et al. Unaffected fellow eye neovascularization in patients with type 3 neovascularization: Incidence and risk factors. PIoS One 2021;16(7):e0254186.
- 9. Sacconi R, Forte P, Capuano V, et al. OCT-A characterization of evolving lesions in fellow eyes of exudative type 3 MNV patients. Retina 2022:10.1097.
- 10. Freund KB, Ho I-V, Barbazetto IA, et al. Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation. Retina 2008;28(2):201-11.
- 11. Najeeb BH, Deak G, Schmidt-Erfurth U, Gerendas BS. The RAP study, report two: the regional distribution of macular neovascularization type 3, a novel insight into its etiology. Retina 2020;40(12):2255-62.
- 12. Haj Najeeb B, Deak GG, Sacu S, et al. The RAP study, report 4: morphological and topographical characteristics of multifocal macular neovascularization type 3. Graefe's Archive for Clinical and Experimental Ophthalmology 2022;260(1):141-7.
- Haj Najeeb B, Deak GG, Schmidt-Erfurth U, Gerendas BS. The RAP study, report 3: Discoloration of the macular region in patients with macular neovascularization type 3. Acta Ophthalmologica 2021.
- 14. Borrelli E, Sacconi R, Klose G, et al. Rotational three-dimensional OCTA: a notable new imaging tool to characterize type 3 macular neovascularization. Scientific Reports 2019;9(1):1-8.
- 15. Shimada H, Kawamura A, Mori R, Yuzawa M. Clinicopathological findings of retinal angiomatous proliferation. Graefe's Archive for Clinical and Experimental Ophthalmology 2007;245(2):295-300.
- 16. Li M, Dolz-Marco R, Messinger JD, et al. Clinicopathologic Correlation of Anti– Vascular Endothelial Growth Factor–Treated Type 3 Neovascularization in Age-Related Macular Degeneration. Ophthalmology 2018;125(2):276-87.
- 17. Sacconi R, Freund KB, Yannuzzi LA, et al. The expanded spectrum of perifoveal exudative vascular anomalous complex. American Journal of Ophthalmology 2017;184:137-46.
- 18. Gilani F, Gal-Or O, Freund KB. Spontaneous rupture and involution of a "macromicroaneurysm" in diabetic retinopathy. Retina 2017;37(6):e73-e4.

- 19. Spaide RF, Barquet LA. Retinal capillary macroaneurysms. Retina 2019;39(10):1889-95.
- 20. Sacconi R, Cohen SY, Borrelli E, et al. Correspondence. Retina 2019;39(11):e48-e9.
- 21. Spaide RF. Correspondence Reply. Retina 2019;39(11):E49-E50.
- 22. Sacconi R, Borrelli E, Sadda S, et al. Nonexudative perifoveal vascular anomalous complex: the subclinical stage of perifoveal exudative vascular anomalous complex? American Journal of Ophthalmology 2020;218:59-67.
- 23. Querques G, Kuhn D, Massamba N, et al. Perifoveal exudative vascular anomalous complex. Journal Français d'Ophtalmologie 2011;34(8):559. e1-. e4.
- 24. Cabral D, Ramtohul P, Fradinho A, Freund KB. Volume Rendering of Deep Retinal Age-Related Microvascular Anomalies. Ophthalmol Retina 2022.
- 25. Chen L, Messinger JD, Sloan KR, et al. Nonexudative macular neovascularization supporting outer retina in age-related macular degeneration: a clinicopathologic correlation. Ophthalmology 2020;127(7):931-47.
- 26. Querques G, Querques L, Forte R, et al. Precursors of type 3 neovascularization: a multimodal imaging analysis. Retina 2013;33(6):1241-8.
- 27. Association WM. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310(20):2191-4.
- Edemekong P, Annamaraju P, Haydel M. Health Insurance Portability and Accountability Act.[Updated 2021 Feb 4]. StatPearls Treasure Island (FL): StatPearls Publishing 2021.
- 29. Rocholz R, Teussink M, Dolz-Marco R, et al. SPECTRALIS optical coherence tomography angiography (OCTA): principles and clinical applications. Heidelb Eng Acad 2018 (September):1-10.
- 30. Cabral D, Fradinho AC, Pereira T, et al. Macular Vascular Imaging and Connectivity Analysis Using High-Resolution Optical Coherence Tomography. Translational Vision Science & Technology 2022;11(6):2-.
- 31. Xu X, Yannuzzi NA, Fernández-Avellaneda P, et al. Differentiating veins from arteries on optical coherence tomography angiography by identifying deep capillary plexus vortices. American Journal of Ophthalmology 2019;207:363-72.
- 32. Kim JH, Chang YS, Kim JW, et al. Characteristics of type 3 neovascularization lesions: focus on the incidence of multifocal lesions and the distribution of lesion location. Retina 2020;40(6):1124-31.
- 33. Group ETDRSR. Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie House classification: ETDRS report number 10. Ophthalmology 1991;98(5):786-806.
- 34. Pongsachareonnont P, Somkijrungroj T, Assavapongpaiboon B, et al. Foveal and parafoveal choroidal thickness pattern measuring by swept source optical coherence tomography. Eye 2019;33(9):1443-51.
- 35. Balaratnasingam C, An D, Sakurada Y, et al. Comparisons between histology and optical coherence tomography angiography of the periarterial capillary-free zone. American Journal of Ophthalmology 2018;189:55-64.
- 36. Litts KM, Messinger JD, Dellatorre K, et al. Clinicopathological correlation of outer retinal tubulation in age-related macular degeneration. JAMA Ophthalmology 2015;133(5):609-12.
- 37. Balaratnasingam C, An D, Freund KB, et al. Correlation between histologic and OCT angiography analysis of macular circulation. Ophthalmology 2019;126(11):1588-9.
- Berlin A MJ, Ferrara D, Freund KB, Curcio CA. OCT features relevant to neovascular AMD management and non-neovascular AMD progression: clinicopathologic correlation. Retinal Cases and Brief Reports 2022; 9900:10.1097.
- 39. Berlin A, Chen L, Messinger J, et al. Double-layer sign in neovascular age-related macular degeneration–do we treat? Acta Ophthalmologica 2022;100(3):348-9.
- Snodderly DM, Weinhaus RS, Choi J. Neural-vascular relationships in central retina of macaque monkeys (Macaca fascicularis). Journal of Neuroscience 1992;12(4):1169-93.

- 41. Balaratnasingam C, Messinger JD, Sloan KR, et al. Histologic and optical coherence tomographic correlates in drusenoid pigment epithelium detachment in age-related macular degeneration. Ophthalmology 2017;124(5):644-56.
- 42. Cao D, Leong B, Messinger JD, et al. Hyperreflective foci, optical coherence tomography progression indicators in age-related macular degeneration, include transdifferentiated retinal pigment epithelium. Investigative Ophthalmology & Visual Science 2021;62(10):34-.
- 43. Najeeb BH, Deak GG, Mylonas G, et al. The RAP study, report 5: rediscovering macular neovascularization Type 3: multimodal imaging of fellow eyes over 24 months. Retina 2022;42(3):485.
- 44. Najeeb BH, Deak GG, Schmidt-Erfurth UM, Gerendas BS. RAP study, report 1: novel subtype of macular neovascularisation type III, cilioretinal MNV3. British Journal of Ophthalmology 2021;105(1):113-7.
- 45. Querques G, Souied EH, Freund KB. How has high-resolution multimodal imaging refined our understanding of the vasogenic process in type 3 neovascularization? Retina 2015; 35(4):603-13.
- 46. Borrelli E, Souied EH, Freund KB, et al. Reduced choriocapillaris flow in eyes with type 3 neovascularization and age-related macular degeneration. Retina 2018; 38(10):1968-76.
- 47. Koizumi H, lida T, Saito M, et al. Choroidal circulatory disturbances associated with retinal angiomatous proliferation on indocyanine green angiography. Graefe's Archive for Clinical and Experimental Ophthalmology 2008;246(4):515-20.
- 48. Spaide RF. Fundus autofluorescence and age-related macular degeneration. Ophthalmology 2003;110(2):392-9.
- 49. Yannuzzi LA, Freund KB, Takahashi BS. Review of retinal angiomatous proliferation or type 3 neovascularization. Retina. 2008; 28(3):375-84
- 50. Cho HJ, Lim SH, Kim J, et al. Assessing the long-term evolution of type 3 neovascularization in age-related macular degeneration using optical coherence tomography angiography. Graefe's Archive for Clinical and Experimental Ophthalmology 2021:1-9.
- 51. Kim JH, Chang YS, Kim JW, et al. Difference in treatment outcomes according to optical coherence tomography–based stages in type 3 neovascularization (retinal angiomatous proliferation). Retina 2018; 38(12):2356-62.
- 52. Sacconi R, Battista M, Borrelli E, et al. OCT-A characterisation of recurrent type 3 macular neovascularisation. British Journal of Ophthalmology 2021;105(2):222-6.
- 53. Huang D, Jia Y, Rispoli M, et al. OCT angiography of time course of choroidal neovascularization in response to anti-angiogenic treatment. Retina 2015;35(11):2260.
- 54. Skalet AH, Miller AK, Klein ML, et al. Clinicopathologic correlation of retinal angiomatous proliferation treated with ranibizumab. Retina 2017;37(8):1620.
- 55. Han JW, Cho HJ, Kang DH, et al. Changes in optical coherence tomography angiography and disease activity in type 3 neovascularization after anti–vascular endothelial growth factor treatment. Retina 2020;40(7):1245-54.
- 56. Timpl R, Brown JC. Supramolecular assembly of basement membranes. Bioessays 1996;18(2):123-32.
- 57. Miner JH, Yurchenco PD. Laminin functions in tissue morphogenesis. Annual Review of Cell and Developmental Biology 2004;20:255.
- 58. Erickson AC, Couchman JR. Still more complexity in mammalian basement membranes. Journal of Histochemistry & Cytochemistry 2000;48(10):1291-306.
- 59. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996;103(11):1820-8.
- 60. Tolentino MJ, Mcleod DS, Taomoto M, et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. American Journal of Ophthalmology 2002;133(3):373-85.

- 61. Jackson TL, Danis RP, Goldbaum M, et al. Retinal vascular abnormalities in neovascular age-related macular degeneration. Retina 2014;34(3):568-75.
- 62. Spaide RF. New proposal for the pathophysiology of type 3 neovascularization as based on multimodal imaging findings. Retina 2019;39(8):1451-64.
- 63. Hayreh SS. Segmental nature of the choroidal vasculature. British Journal of Ophthalmology 1975;59(11):631-48.
- 64. Hayreh SS. In vivo choroidal circulation and its watershed zones. Eye 1990;4(2):273-89.
- 65. Hayreh SS. Posterior ciliary artery circulation in health and disease the Weisenfeld lecture. Investigative Ophthalmology & Visual Science 2004;45(3):749-57.
- 66. Yamazaki T, Koizumi H, Yamagishi T, Kinoshita S. Subfoveal choroidal thickness in retinal angiomatous proliferation. Retina 2014;34(7):1316-22.
- 67. Kim JH, Kim JR, Kang SW, et al. Thinner choroid and greater drusen extent in retinal angiomatous proliferation than in typical exudative age-related macular degeneration. American journal of ophthalmology 2013;155(4):743-9. e2.
- 68. Tan R, Guymer RH, Luu CD. Subretinal drusenoid deposits and the loss of rod function in intermediate age-related macular degeneration. Investigative Ophthalmology & Visual Science 2018;59(10):4154-61.
- 69. Tan RS, Guymer RH, Aung K-Z, et al. Longitudinal assessment of rod function in intermediate age-related macular degeneration with and without reticular pseudodrusen. Investigative Ophthalmology & Visual Science 2019;60(5):1511-8.
- 70. Chen KG, Alvarez JA, Yazdanie M, et al. Longitudinal study of dark adaptation as a functional outcome measure for age-related macular degeneration. Ophthalmology 2019;126(6):856-65.
- 71. Zhang Y, Sadda SR, Sarraf D, et al. Spatial Dissociation of Subretinal Drusenoid Deposits and Impaired Scotopic and Mesopic Sensitivity in AMD. Investigative Ophthalmology & Visual Science 2022;63(2):32-.
- 72. Nigalye AK, Hess K, Pundlik SJ, et al. Dark Adaptation and Its Role in Age-Related Macular Degeneration. Journal of Clinical Medicine 2022;11(5):1358.
- 73. Zheng F, Zhang Q, Shi Y, et al. Age-dependent changes in the macular choriocapillaris of normal eyes imaged with swept-source optical coherence tomography angiography. American Journal of Ophthalmology 2019;200:110-22.
- Ingram NT, Fain GL, Sampath AP. Elevated energy requirement of cone photoreceptors. Proceedings of the National Academy of Sciences 2020;117(32):19599-603.
- 75. Borrelli E, Mastropasqua L, Souied E, et al. Longitudinal assessment of type 3 macular neovascularization using three-dimensional volume-rendering optical coherence tomography angiography. Canadian Journal of Ophthalmology 2021.



Figure S2. Hyperfluorescence without histologic correlate, OS 2

A. Fluorescein angiography (FA, **A1**) venous phase, 11 months before death, shows multiple instances of hyperfluorescence. An optical coherence tomography (OCT) B-scan (green line) displays drusen, a double-layer sign (white arrowhead), choroidal hypertransmission, and hyperreflective foci (**A2**).

B, **C**. At 4 and 2 months before death, with 5 (**B**) and 6 (**C**) total injections, respectively, the lesion is stable, without intraretinal cysts.



Figure S3. Initial presentation of right eye, 5 years before death

A-E. Fluorescein angiography (FA), near infrared reflectance images (NIR), and radial optical coherence tomography (OCT) B-scans show exudative age-related macular degeneration in the right eye at initial presentation. Based on these findings anti-VEGF therapy is initiated.
A. FA recirculation phase shows marked leakage. Corresponding OCT shows intraretinal and subretinal hyporeflective cysts and spaces representing exudation, located above drusenoid pigment epithelium detachments in the fovea and parafovea.

B. NIR and OCT show hyporeflective subretinal drusenoid deposits and hyperreflective soft drusen across the macula. Hyperreflective foci are present in inner and outer nuclear layer.



Figure S4. Initial presentation of left eye, 5 years before death

A-E. Near infrared reflectance images (NIR) and radial optical coherence tomography (OCT) B-scans show non-exudative age-related macular degeneration in the left eye. Hyporeflective subretinal drusenoid deposits and hyperreflective soft drusen (**B** teal and fuchsia arrowheads respectively) appear across the macula.

B. On the recirculation phase of fluorescein angiography (FA), no intraretinal or subretinal fluid or leakage is present, ensuring absence of active MNV exudation.

F. A shallow RPE elevation with choroidal hypertransmission (white arrowhead) and hyperreflective focus was stable on longitudinal follow-up by OCT (**Figure S4**). No vessel was found in histology. This lesion presumably corresponds to a calcified druse.³⁸



medRxiv preprint doi: https://doi.org/10.1101/2022.09.13.22279910; this version posted December 28, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure S10. Tangled vascular complex in type 3 MNV, OD 1.

A-C. Tangled vascular complex (fuchsia arrowheads indicate lumen) spans 249 μ m horizontally towards the superior perifovea (**A**, 759 μ m from fovea; **B**, 719 μ m from fovea; **C**, 552 μ m from fovea). The complex is partly ensheathed by collagenous material and is flanked by retinal pigment epithelium (RPE) cells. Two cells rest entirely within the outer plexiform layer (OPL)/ inner nuclear layer (INL; light blue arrowhead in **A**). The INL/OPL subsides, and the vascular complex extends from the INL/OPL border through the Henle fiber layer (HFL)/ outer nuclear layer (ONL). The complex adheres to basal laminar deposits (BLamD) draping a calcified druse (d). Bruch's membrane (BrM) appears intact without evidence of a choroidal contribution. The external limiting membrane (ELM) descends at both edges of the calcified druse (yellow arrowheads in **B**). Vessel walls do not exhibit obvious arterial or venous features. Vessel diameter within the INL was larger than 15 μ m, suggesting drainage venules.



Figure S14. Transmission electron microscopy of DRAMA with RPE complex, OS 3.

The Vessel is ensheathed by an endothelial (E) cell and a pericyte (P), with little collagen. The Lumen contains a leukocyte (LC) and a red blood cell (RBC). The surrounding tower of retinal pigment epithelium (RPE) is multicellular (white asterisk), and multinucleated (fuchsia asterisks). RPE organelle packing density and electron-density is similar to in-layer RPE cells (not shown).